JP2022550658A5 - - Google Patents

Info

Publication number
JP2022550658A5
JP2022550658A5 JP2022502409A JP2022502409A JP2022550658A5 JP 2022550658 A5 JP2022550658 A5 JP 2022550658A5 JP 2022502409 A JP2022502409 A JP 2022502409A JP 2022502409 A JP2022502409 A JP 2022502409A JP 2022550658 A5 JP2022550658 A5 JP 2022550658A5
Authority
JP
Japan
Prior art keywords
buffer
bladder
composition
heparin
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022502409A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550658A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/041977 external-priority patent/WO2021011566A1/en
Publication of JP2022550658A publication Critical patent/JP2022550658A/ja
Publication of JP2022550658A5 publication Critical patent/JP2022550658A5/ja
Pending legal-status Critical Current

Links

JP2022502409A 2019-07-18 2020-07-14 膀胱痛症状の緩和を促進するための、膀胱内ヘパリンおよびアルカリ化リドカインによる治療前の、膀胱壁のアルカリ化 Pending JP2022550658A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962875745P 2019-07-18 2019-07-18
US62/875,745 2019-07-18
PCT/US2020/041977 WO2021011566A1 (en) 2019-07-18 2020-07-14 Alkalization of urinary bladder wall prior to treatment with intravesical heparin and alkalinized lidocaine to enhance relief of bladder pain symptoms

Publications (2)

Publication Number Publication Date
JP2022550658A JP2022550658A (ja) 2022-12-05
JP2022550658A5 true JP2022550658A5 (enExample) 2024-06-18

Family

ID=74211195

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502409A Pending JP2022550658A (ja) 2019-07-18 2020-07-14 膀胱痛症状の緩和を促進するための、膀胱内ヘパリンおよびアルカリ化リドカインによる治療前の、膀胱壁のアルカリ化

Country Status (6)

Country Link
US (1) US20220273587A1 (enExample)
EP (1) EP3998932A4 (enExample)
JP (1) JP2022550658A (enExample)
AU (1) AU2020315353A1 (enExample)
CA (1) CA3147731A1 (enExample)
WO (1) WO2021011566A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12702790B2 (en) 2019-06-13 2026-08-11 Hollister Incorporated Reusable urinary catheter kits
LT3952973T (lt) 2019-06-13 2023-07-10 Hollister Incorporated Daugkartinio naudojimo šlapimo kateterio produktai
WO2020263859A1 (en) 2019-06-25 2020-12-30 Hollister Incorporated Reusable urinary catheter products

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6183461B1 (en) * 1998-03-11 2001-02-06 Situs Corporation Method for delivering a medication
US20050238733A1 (en) * 2000-01-05 2005-10-27 Richard Henry Topical anesthesia of the urinary bladder
CA2554489A1 (en) * 2004-01-28 2005-08-11 The Regents Of The University Of California Novel interstitial therapy for immediate symptom relief and chronic therapy in interstitial cystitis
FR2967577B1 (fr) * 2010-11-18 2013-07-12 Advicenne Pharma Composition pharmaceutique comprenant du sel de bicarbonate, et son utilisation comme medicament
EA201391014A1 (ru) * 2011-01-06 2014-01-30 С. Лоуэлл Парсонс Способ производства композиции, содержащей местный анестетик, гепариноид и буфер
US20150359816A1 (en) * 2013-01-28 2015-12-17 Urigen Pharmaceuticals, Inc. Stable compositions comprising heparinoid, acute-acting anesthetic, and buffer
JP7862118B2 (ja) 2017-04-12 2026-05-19 ウリゲン ファーマシューティカルズ、インコーポレイテッド 改善された安定性を備えた注射器中に局所麻酔薬、緩衝液、およびグルコサミノグリカンを含む製品

Similar Documents

Publication Publication Date Title
CN1310651C (zh) 用于眼科和鼻科的药物组合物
CA2266811C (en) Method and composition for wound treatment
DE10161149B4 (de) Verwendung von Heparin-haltigem Ophthalmikum
CN1227493A (zh) 肝素或硫酸乙酰肝素与脱乙酰壳多糖结合用于预防或治疗由疱疹病毒引起的感染
ES2748058T3 (es) Kits y composiciones para tratar trastornos del tracto urinario inferior
US20140038917A1 (en) Sterile and injectable aqueous formulation for administration in the intra-articular space of an intra-articular joint
CN108601768A (zh) 用于治疗老花眼的组合物
KR20160008496A (ko) 헤파리노이드, 급성 작용성 마취제 및 버퍼를 포함하는 안정한 조성물
US10898613B2 (en) Hyaluronic acid gel with a divalent zinc cation
RU2011152518A (ru) Применение композиции для лечения мукозита
JP6842794B2 (ja) 皮膚外用製剤
TWI612965B (zh) 玻尿酸之用途及疼痛抑制用醫藥組成物
CN1758920A (zh) 采用高剂量硫酸软骨素的膀胱炎疗法
WO2011097148A2 (en) Use of oral heparin preparations to treat urinary tract diseases and conditions
JP6474193B2 (ja) 局所麻酔剤、ヘパリノイド、及び緩衝剤を含む組成物を製造する方法
JP2005145963A (ja) 鼻炎の処置のための医薬組成物
CN111939179A (zh) 眼镜蛇蛇毒或其提取物在制备降尿酸和/或抗痛风性关节炎的药物中的应用
AU2020315353A1 (en) Alkalization of urinary bladder wall prior to treatment with intravesical heparin and alkalinized lidocaine to enhance relief of bladder pain symptoms
EP1793836A2 (en) Ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan and methods of using the same
CA2779937C (en) Pharmaceutical composition for the treatment of bladder disorders
WO2021101883A1 (en) Chitosan containing compositions and methods relating to same
CA2516318A1 (en) Use of glycosaminoglycans such as heparin for the treatment of respiratory disorders such as copd
RU2414908C2 (ru) Фармацевтическая композиция для лечения остеоартрита, содержащая клодроновую кислоту и гиалуроновую кислоту
EA009209B1 (ru) Фармацевтическая композиция, содержащая цинк-гиалуронановый комплекс, предназначенная для лечения рассеянного склероза
EP3407899B1 (de) Immunprophylaxe bei rezidivierenden bakteriellen infektionen